BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $205,000 | -16.7% | 3,806 | -0.7% | 0.17% | -8.1% |
| Q2 2022 | $246,000 | -17.2% | 3,831 | 0.0% | 0.18% | -2.1% |
| Q1 2022 | $297,000 | -9.7% | 3,831 | 0.0% | 0.19% | -2.1% |
| Q4 2021 | $329,000 | +6.8% | 3,831 | 0.0% | 0.19% | -3.0% |
| Q3 2021 | $308,000 | 0.0% | 3,831 | 0.0% | 0.20% | +0.5% |
| Q2 2021 | $308,000 | -4.9% | 3,831 | 0.0% | 0.20% | -10.8% |
| Q1 2021 | $324,000 | +5.5% | 3,831 | 0.0% | 0.22% | +1.8% |
| Q4 2020 | $307,000 | -0.3% | 3,831 | 0.0% | 0.22% | -9.9% |
| Q3 2020 | $308,000 | -6.7% | 3,831 | 0.0% | 0.24% | -15.4% |
| Q2 2020 | $330,000 | +6.1% | 3,831 | 0.0% | 0.29% | -9.2% |
| Q1 2020 | $311,000 | -2.8% | 3,831 | 0.0% | 0.32% | +27.5% |
| Q4 2019 | $320,000 | -4.5% | 3,831 | 0.0% | 0.25% | -16.8% |
| Q3 2019 | $335,000 | +6.7% | 3,831 | 0.0% | 0.30% | +7.6% |
| Q2 2019 | $314,000 | +0.6% | 3,831 | 0.0% | 0.28% | 0.0% |
| Q1 2019 | $312,000 | +23.8% | 3,831 | 0.0% | 0.28% | +11.3% |
| Q4 2018 | $252,000 | -12.2% | 3,831 | +2.8% | 0.25% | +1.6% |
| Q3 2018 | $287,000 | +4.4% | 3,725 | 0.0% | 0.24% | -1.2% |
| Q2 2018 | $275,000 | +13.6% | 3,725 | 0.0% | 0.25% | +13.3% |
| Q1 2018 | $242,000 | +0.4% | 3,725 | 0.0% | 0.22% | +5.8% |
| Q4 2017 | $241,000 | +3.0% | 3,725 | 0.0% | 0.21% | -2.8% |
| Q3 2017 | $234,000 | +3.5% | 3,725 | 0.0% | 0.21% | +2.9% |
| Q2 2017 | $226,000 | -32.9% | 3,725 | -42.8% | 0.21% | -31.8% |
| Q1 2017 | $337,000 | +8.7% | 6,513 | -6.7% | 0.30% | +7.5% |
| Q4 2016 | $310,000 | -6.6% | 6,977 | 0.0% | 0.28% | -6.6% |
| Q3 2016 | $332,000 | +13.7% | 6,977 | +8.3% | 0.30% | +13.6% |
| Q2 2016 | $292,000 | +13.6% | 6,443 | +2.9% | 0.26% | +6.4% |
| Q1 2016 | $257,000 | +7.5% | 6,263 | 0.0% | 0.25% | 0.0% |
| Q4 2015 | $239,000 | +11.7% | 6,263 | -3.9% | 0.25% | +3.3% |
| Q3 2015 | $214,000 | -48.9% | 6,516 | +8.7% | 0.24% | -46.0% |
| Q2 2015 | $419,000 | +2.4% | 5,995 | +0.5% | 0.45% | +0.2% |
| Q1 2015 | $409,000 | -9.7% | 5,965 | -3.3% | 0.44% | -1.8% |
| Q4 2014 | $453,000 | +2.3% | 6,170 | 0.0% | 0.45% | +4.6% |
| Q3 2014 | $443,000 | +2.8% | 6,170 | +3.6% | 0.43% | +9.6% |
| Q2 2014 | $431,000 | -6.9% | 5,955 | -5.3% | 0.40% | -13.2% |
| Q1 2014 | $463,000 | +5.9% | 6,290 | 0.0% | 0.46% | +4.6% |
| Q4 2013 | $437,000 | +3.1% | 6,290 | -2.5% | 0.44% | -8.8% |
| Q3 2013 | $424,000 | -8.2% | 6,450 | -3.4% | 0.48% | -11.7% |
| Q2 2013 | $462,000 | – | 6,675 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |